Edition:
India

Hikma Pharmaceuticals Reports 7 Pct Rise In FY Group Revenue


Wednesday, 13 Mar 2019 

March 13 (Reuters) - Hikma Pharmaceuticals PLC ::HIKMA PHARMACEUTICAL - FINAL RESULTS.HIKMA PHARMACEUTICALS PLC - FY GROUP CORE REVENUE OF $2,076 MILLION, UP 7%.HIKMA PHARMACEUTICALS PLC - FY GROUP CORE OPERATING PROFIT OF $460 MILLION, UP 19%.HIKMA PHARMACEUTICALS PLC - FY GROUP REVENUE OF $2,070 MILLION, UP 7%.HIKMA PHARMACEUTICALS PLC - FY GROUP OPERATING PROFIT OF $371 MILLION.HIKMA PHARMACEUTICALS PLC - PROPOSED FULL YEAR DIVIDEND OF 38 CENTS PER SHARE, UP FROM 34 CENTS PER SHARE.HIKMA PHARMACEUTICALS PLC - STRONG PERFORMANCE IN 2018, WITH REVENUE AND PROFITABILITY SIGNIFICANTLY AHEAD OF OUR EXPECTATIONS AT START OF YEAR.HIKMA PHARMACEUTICALS PLC - INJECTABLES BUSINESS CONTINUED TO PERFORM VERY WELL.HIKMA PHARMACEUTICALS PLC - IN 2018 GLOBAL INJECTABLES CORE REVENUE UP 7% TO $832 MILLION (2017: $776 MILLION).HIKMA PHARMACEUTICALS PLC - IN 2019, WE EXPECT GLOBAL INJECTABLES REVENUE TO BE IN RANGE OF $850 MILLION TO $900 MILLION.HIKMA PHARMACEUTICALS PLC - EXPECT REVENUE GROWTH FROM NEW PRODUCT LAUNCHES AND GOOD DEMAND FOR OUR IN-MARKET PORTFOLIO IN INJECTABLES IN 2019.HIKMA PHARMACEUTICALS PLC - IN 2018 GENERICS REVENUE GREW 13% TO $692 MILLION (2017: $615 MILLION).HIKMA PHARMACEUTICALS PLC - WE EXPECT GENERICS REVENUE TO BE IN RANGE OF $650 MILLION TO $700 MILLION IN 2019.HIKMA PHARMACEUTICALS PLC - IN 2019 EXPECT INJECTABLES CORE OPERATING MARGIN TO BE IN RANGE OF 35% TO 38%.